Procaspase 3 activation by combination therapy
US10888560B2 · kind B2 · utility
0Cited by
12References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 1, 2018 |
| Grant date | Jan 12, 2021 |
| Priority date | — |
| Expiry date | Oct 20, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.